Article
Lutein inhibits tumor progression through the ATR /Chk1/p53 signaling pathway in non‐small cell lung cancer
21 Nov 2022
Abstract excerpt
Lung cancer is the leading cause of cancer-related death. In particular, non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. Due to tumor resistance and the toxicity of chemotherapeutic agents, it is increasingly critical to discover novel, potent antitumorigenic drugs for treating NSCLC. Lutein, a carotenoid, has been reported to exert toxic effects on cells in several...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
